Details of the Drug Formulations

General Information of Drug (ID: DM7Q98D)

• Drug Name: Ruxolitinib Drug Info
• Synonyms: Ruxolitinib (JAK inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Essential thrombocythemia	3B63.1Z	Approved	[1]
High-risk myelofibrosis	2A20.2	Approved	[2]
Myelofibrosis	2A22	Approved	[3]
Myeloproliferative neoplasm	2A20	Approved	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[5]
Pancreatic cancer	2C10	Phase 3	[2]
Atopic dermatitis	EA80	Phase 1/2	[6]
Vitiligo	ED63.0	Phase 1/2	[6]

• Cross-matching ID:
  PubChem CID: 25126798
  ChEBI ID: CHEBI:66919
  CAS Number: 941678-49-5
  TTD ID: D04LKS
  ACDINA ID: D00611

Full List of Drug Formulations Containing This Drug

Ruxolitinib Phosphate eq 5mg base tablet

Company	Formulation ID	FDA Description
yte Corp	F23988	Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose

Ruxolitinib Phosphate eq 10mg base tablet

Company	Formulation ID	FDA Description
yte Corp	F23989	Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose

Ruxolitinib Phosphate eq 15mg base tablet

Company	Formulation ID	FDA Description
yte Corp	F23990	Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose

Ruxolitinib Phosphate eq 20mg base tablet

Company	Formulation ID	FDA Description
yte Corp	F23991	Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose

Ruxolitinib Phosphate eq 25mg base tablet

Company	Formulation ID	FDA Description
yte Corp	F23992	Microcrystalline Cellulose; Lactose Monohydrate; Magnesium Stearate; Colloidal Silicon Dioxide; Sodium Starch Glycolate; Povidone; Hydroxypropyl Cellulose

Ruxolitinib 10 mg tablet

Company	Formulation ID	FDA Description
Incyte Corporation	F19707	Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato

Ruxolitinib 15 mg tablet

Company	Formulation ID	FDA Description
Incyte Corporation	F19708	Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato

Ruxolitinib 20 mg tablet

Company	Formulation ID	FDA Description
Incyte Corporation	F19709	Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato

Ruxolitinib 25 mg tablet

Company	Formulation ID	FDA Description
Incyte Corporation	F19710	Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato

Ruxolitinib 5 mg tablet

Company	Formulation ID	FDA Description
Incyte Corporation	F19711	Lactose monohydrate; Magnesium stearate; Povidone; Silicon dioxide; Cellulose, microcrystalline; Hydroxypropyl cellulose (type e); Sodium starch glycolate type a potato

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Ruxolitinib FDA Label
• [5] Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)